Cancer drugs account for 27% of all new drug approvals in the U.S., says Tufts
Cancer drugs currently account for 27% of all new drug approvals in the U.S. since 2010, a dramatic increase from the 4% share of the 1980s, a newly completed analysis from the Tufts Center for the Study of Drug Development shows. From 1980 through 2018, the Food and Drug Administration approved a total of 126… Read More »